RxDoctor Payments Data

Moise Anglade, MD

Cardiovascular Disease · Atlantis, FLNPI 1992904718

Payments from drug & device makers

$29,273in general payments, 2019–2025

Across 278 payments — averaging $105.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$15K
  • Amgen$9K
  • Abbott$2K
  • Medtronic$2K
  • Johnson & Johnson$543
  • Boston Scientific$259
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,47731%
  • Travel & lodging$2,75825%
  • Food & beverage$4,78443%
  • Education$2012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,273 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$689,170
Medicare patients
876
Services billed
5,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban521$505,072
XareltoRivaroxaban391$373,172
EntrestoSacubitril/Valsartan333$339,582
FarxigaDapagliflozin Propanediol125$100,175
MultaqDronedarone Hcl58$69,883
JardianceEmpagliflozin66$57,822
BrilintaTicagrelor53$32,483
Ranolazine ErRanolazine141$15,976
Repatha SureclickEvolocumab12$11,103
Amiodarone Hcl213$8,945
NexletolBempedoic Acid13$8,940
Metoprolol Succinate1,103$8,809
Praluent PenAlirocumab11$8,527
Repatha SyringeEvolocumab12$7,654
Carvedilol782$4,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$151$505,072521 claims
Johnson & JohnsonXarelto$543$373,172391 claims
NovartisEntresto$14,630$339,582333 claims
AstraZenecaFarxiga, Brilinta$173$132,658178 claims
Sanofi-aventis U.S. LLCMultaq$38$69,88358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →